Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06666192 · ClinicalTrials.gov registry record · NA
The Ohio State University (OSU) SCREEN Community Program
A NA study of Breast Carcinoma and Colorectal Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 2,067
- Enrollment target
- 1
- Study location
NCT06666192: Recruiting NA study of Breast Carcinoma and Colorectal Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.
NCT06666192 is a NA study of Breast Carcinoma and Colorectal Carcinoma that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 2,067 participants, above the 751-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (175% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06666192, a NA study of Breast Carcinoma and Colorectal Carcinoma, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,067 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial develops and tests how well a multi-level intervention (MLI), The Ohio State University (OSU) SCREEN Community Program, works to increase screening and follow-up for breast, cervical and colorectal (CRC) cancer among low-income and un/underinsured female residents in three counties in Central Ohio. In Ohio, incidence and mortality rates for breast, cervical and CRC are higher than or similar to the national average; in addition, underserved populations - minority, rural and low-income women - have higher rates of these cancers. Screening can detect precancerous colorectal and cervical lesions and other early-stage cancers when treatment is less intensive and more successful and is known to reduce mortality rates for breast, cervical, and CRC, however many of these women lack access to health care and screenings. This MLI includes clinic-based components, such as patient education, as well as community-based strategies, such as media programs and training health workers, that can increase rates of guideline-recommended breast, cervical and CRC screening and follow-ups in underserved populations. The OSU SCREEN Community Program may be an effective way to improve breast, cervical and CRC screenings among underserved women in Ohio.
Primary Outcome
Will be assessed by the difference in proportions of being UTD with all age-appropriate screening tests using electronic health record (EHR) data. Rates will be examined by age, race/ethnicity, residence, payer status, provider, time since last visit, and rates of other cancer screening. Repeated measure Generalized Estimating Equations (GEE) models with compound symmetry correlation structure and robust variance will be used to compare change between the early and delayed intervention groups ad
Conditions Studied
Interventions
- OTHER Educational Intervention
- OTHER Discussion
- BEHAVIORAL Focus Group
- OTHER Educational Activity
- OTHER Cancer Screening
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,067 participants |
| Start Date | 2024-03-12 |
| Est. Completion | 2029-12-31 |
| Phase | NA |
What NCT06666192 shows while recruiting
NCT06666192 is an interventional study that assigns participants to a tested intervention. Its 2,067 participants enrollment target places it among the larger protocols in the corpus, above the 751-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (175% higher).
The record links to 3 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Educational Intervention is the first listed.
NCT06666192 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06666192 about?
NCT06666192 is a clinical study titled "The Ohio State University (OSU) SCREEN Community Program". This clinical trial develops and tests how well a multi-level intervention (MLI), The Ohio State University (OSU) SCREEN Community Program, works to increase screening and follow-up for breast, cervical and colorectal (CRC) cancer among low-income and un/underinsured female residents in three counti...
What is the current status of trial NCT06666192?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,067 participants. The study started on 2024-03-12. Estimated completion is 2029-12-31.
What conditions does trial NCT06666192 study?
This clinical trial studies the following conditions: Breast Carcinoma, Colorectal Carcinoma, Cervical Carcinoma.
What interventions are being tested in trial NCT06666192?
The interventions under investigation include: Educational Intervention (OTHER), Discussion (OTHER), Focus Group (BEHAVIORAL), Educational Activity (OTHER), Cancer Screening (OTHER).
Who is sponsoring clinical trial NCT06666192?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06666192 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06666192's enrollment target sits among peer trials
2,067 7th of 106 higher than 100 of 106 other Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New York
RECRUITING · NA
-
Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer
RECRUITING · NA
-
An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
RECRUITING · NA
-
A 3D-Printed External Breast Prosthesis for the Improvement of Patient-reported Outcomes Among Breast Cancer Patients That Underwent a Mastectomy Without Reconstruction
RECRUITING · NA
-
Cancer Genetic Testing in Ethnic Populations
RECRUITING · NA
-
Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00588068 · 2,070 participants
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
- NCT07168993 · 2,063 participants · NA
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
- NCT04871542 · 2,062 participants
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
- NCT06521944 · 2,062 participants
RSV Vaccine Pregnancy Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI